Amyloid-β

D-688 is a potent inhibitor of Tau and amyloid-beta (Aβ), demonstrating significant neuroprotective properties. This compound effectively reverses Aβ1–42-induced toxicity in SH-SY5Y neuronal cells, making it a valuable tool for studying neurodegenerative processes. Additionally, D-688 improves the survival rate of Drosophila melanogaster models expressing the human tau protein isoform (2N4R), underscoring its potential in Alzheimer's disease research and related disorders.

Beauveriolide III is a specific inhibitor of lipid droplet formation, effectively reducing lipid accumulation in mouse macrophages. This compound plays a significant role in studies focused on lipid metabolism and its implications in metabolic disorders. Its utility in research can aid in understanding the biological pathways regulating lipid storage and inflammation in macrophage-associated pathologies.

RAGE/SERT-IN-1 is a potent inhibitor of receptor for advanced glycation end products (RAGE) and serotonin transporter (SERT), demonstrating IC50 values of 8.26 μM and 31.09 nM, respectively. This compound exhibits significant neuroprotective properties against Aβ25-35-induced neuronal damage and has been shown to alleviate depressive behaviors in murine models. RAGE/SERT-IN-1 is a valuable tool for studying the interplay between Alzheimer's disease and depression comorbidity.

SEN 304 is an Aβ aggregation inhibitor that directly binds to Aβ(1-42), effectively delaying β-sheet formation while promoting the aggregation of toxic oligomers into a nontoxic form. This compound is primarily utilized in research focused on Alzheimer’s disease, providing insights into the mechanisms of neurodegeneration and potential therapeutic strategies. The ability of SEN 304 to modulate Aβ aggregation makes it a valuable tool for studying amyloid pathology.

Aβ Fibrillization Modulator 1 targets amyloid-β (Aβ) by stabilizing Aβ monomers, thus inhibiting the formation of toxic fibrils associated with neurodegenerative diseases. This compound demonstrates potential in research applications focused on Alzheimer's disease and other amyloid-related disorders. By modulating fibrillization, it provides a valuable tool for investigating the mechanisms of amyloid aggregation and the development of therapeutic strategies.

2002-G12 is an Aβ42 inhibitor that effectively reduces Aβ42 toxicity by 76%. Its mechanism of action makes it a valuable tool for investigating Alzheimer's disease and studying the role of Aβ42 in neurodegenerative processes. Researchers can utilize 2002-G12 to explore potential therapeutic strategies targeting amyloid-beta aggregation and toxicity.

KMS88009 is a potent amyloid-β oligomer inhibitor that directly disrupts the formation of these aggregates. This compound demonstrates significant potential in preserving cognitive function when administered preventively and reversing cognitive decline therapeutically. In studies using the APP/PS1 double transgenic mouse model, KMS88009 effectively reduced amyloid-β oligomer assembly and improved cognitive performance. Comprehensive evaluations of its physicochemical properties, pharmacokinetics, and toxicity further underscore KMS88009's promise as a therapeutic candidate for Alzheimer's disease.

β-Secretase-IN-5 is a potent inhibitor of beta-secretase, a key enzyme involved in the cleavage of amyloid precursor protein (APP). By selectively reducing the production of amyloid-beta peptides Aβ1-40 and Aβ1-42, this compound is essential for research into Alzheimer's disease mechanisms and therapeutic strategies. Its application in neurodegenerative studies provides valuable insights into potential treatments for Alzheimer's.

SEN-1269 is a potent inhibitor of Aβ aggregation, specifically targeting Aβ(1-42) oligomers. This compound protects neuronal cell lines from the detrimental effects of Aβ(1-42) exposure and mitigates deficits in long-term potentiation (LTP) and memory associated with Aβ oligomer toxicity. SEN-1269 serves as a valuable tool for research investigating the pathophysiology of Alzheimer's disease.

GL-522, a 4-sulfocalix[8]arene derivative, functions as an Aβ42 inhibitor by engaging in nonspecific and multipoint hydrophobic interactions, exhibiting a Kd of 276 μM. This compound effectively inhibits the fibrillation of Aβ42 and mitigates its cytotoxic effects, making it a valuable tool for research in Alzheimer's disease. Its ability to modulate amyloid aggregation and toxicity positions GL-522 as a significant reagent in neurodegenerative disease studies.

AY1511 is an amyloid β (Aβ) aggregation inhibitor that demonstrates low cytotoxicity. This compound is utilized in research focusing on neurodegenerative diseases, particularly Alzheimer's disease, by inhibiting the aggregation of Aβ peptides. AY1511 serves as a valuable tool for studying the mechanisms of amyloid pathology and the development of potential therapeutic strategies.

Tau/Aβ40 aggregation-IN-1 is a potent inhibitor of tau and Aβ40 aggregation, exhibiting IC50 values of 1.8 μM and 1.3 μM, respectively. This compound is of significant interest in Alzheimer's disease research, as it targets the pathological aggregation of tau protein and amyloid-beta peptides. Its effectiveness in modulating these protein interactions makes it a valuable tool for studying neurodegenerative mechanisms and potential therapeutic interventions.

Aβ-IN-4 is a potent inhibitor of amyloid β (Aβ) aggregation, specifically targeting Aβ42. It effectively halts the aggregation process of Aβ42, which is central to the pathogenesis of Alzheimer’s disease. However, Aβ-IN-4 does not mitigate the neurotoxicity associated with Aβ42 in SH-SY5Y cells, nor does it modify the aggregation state of Aβ42 into a non-toxic form. This compound is valuable for research investigating Aβ-related mechanisms and the development of Alzheimer’s therapeutics.

AZ4800 is an amyloid-β inhibitor that targets the processing of amyloid precursor protein. It effectively reduces Aβ42 levels, demonstrating additive lowering activity both in vitro and in vivo. This compound is valuable for research focusing on Alzheimer's disease and related neurodegenerative disorders.

TAK-070 hydrochloride hydrate is a noncompetitive inhibitor of BACE1 with an IC50 value of 3.15 μM. This compound is actively researched for its potential therapeutic effects in Alzheimer's disease, demonstrating the ability to reduce brain levels of soluble Aβ. Additionally, TAK-070 hydrochloride hydrate has shown promise in ameliorating cognitive impairments in preclinical models of Alzheimer's disease, making it a valuable tool for studying neurodegenerative disorders.

RI-OR2 is an amyloid-β (Aβ) oligomerization inhibitor that functions as a retro-inverso peptide. It has been shown to bind effectively to immobilized β-Amyloid (1-42) monomers and fibrils, demonstrating an apparent dissociation constant (Kd) of 9-12 μM. Additionally, RI-OR2 inhibits the extension of Aβ(1-42) fibrils, making it a valuable tool for research into Alzheimer’s disease and the mechanisms of amyloid pathology.

RU-505 is a potent inhibitor of the β-amyloid (Aβ) and fibrinogen interaction, demonstrating IC50 values of 5.00 μM and 2.72 μM in fluorescence polarization and AlphaLISA assays, respectively. This compound exhibits high permeability across the blood-brain barrier (BBB), making it a valuable tool in targeting cerebral amyloid angiopathy (CAA). RU-505 is applicable in research studies focused on Alzheimer's disease (AD) pathogenesis and potential therapeutic interventions.

TAK-070 Free base is a noncompetitive inhibitor of BACE1 with an IC50 of 3.15 μM. This compound exhibits significant potential in Alzheimer's disease research by reducing brain levels of soluble Aβ and ameliorating cognitive deficits in AD models. Its ability to modulate amyloid-beta processing makes it a valuable tool for investigating therapeutic strategies targeting Alzheimer's pathology.

TPI-1917-49 is an Aβ inhibitor that effectively crosses the blood-brain barrier to decrease levels of amyloid beta (Aβ) peptide segments. By promoting the non-amyloidogenic pathway of amyloid precursor protein (APP), TPI-1917-49 enhances the generation of soluble APPα through α-secretase activity, thereby reducing amyloid plaque formation in murine models. This compound is suitable for research investigating Alzheimer's disease and its related pathologies.

Aβ-IN-1 is an Aβ1-42 aggregation inhibitor that effectively prevents the aggregation of Aβ1-42 peptides in vitro. By delaying the exponential growth phase and reducing the steady-state quantity of fibrils, Aβ-IN-1 serves as a valuable tool for studying conformational disorders. This reagent is particularly relevant for research focused on Alzheimer's disease and other amyloid-related pathologies.

BSBM6 is an amyloid-β (Aβ) inhibitor that effectively prevents Aβ aggregation and modulates its formation. This compound has been shown to reduce soluble oligomers, thereby potentially aiding in the treatment of neurodegenerative diseases associated with amyloid pathology. BSBM6 serves as a valuable tool for researchers studying Aβ dynamics and for the design of novel aggregation-modulating ligands.

CHF5022 is an inhibitor of Aβ42 secretion, exhibiting an IC50 value of 92 μM. In addition to its primary activity, CHF5022 demonstrates modest inhibition of Aβ40 at non-cytotoxic concentrations, achieving a reduction of approximately 22.2% at 100 μM. This compound is valuable for research into Alzheimer's disease and the mechanisms of amyloid-beta peptide regulation.

Kayaflavone is a biflavonoid of the amentoflavone type known for its inhibitory activity against amyloid-β42 cytotoxicity in PC-12 cells, exhibiting an EC50 value of 5.29 μM. This compound holds potential for research applications in Alzheimer’s disease, contributing to the understanding of amyloid-related neurotoxicity and its implications in neurodegenerative processes.

Azeliragon dihydrochloride is a selective inhibitor of the receptor for advanced glycation end products (RAGE). This compound demonstrates the ability to cross the blood-brain barrier and has been investigated for its potential to mitigate disease progression in patients with mild Alzheimer's disease. Its mechanism of action involves reducing neuroinflammation and promoting neuronal health, making it a promising candidate for research focused on Alzheimer's disease therapeutics.

Dihydroergocristine mesylate is a potent inhibitor of γ-secretase, targeting the enzyme responsible for the generation of amyloid-β peptides implicated in Alzheimer’s disease. It effectively reduces the production of these peptides by binding directly to γ-secretase and Nicastrin, exhibiting equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively. This compound can be utilized in research aimed at unraveling the mechanisms of Alzheimer’s pathology and developing potential therapeutic strategies.